A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients
Latest Information Update: 20 Jan 2022
Price :
$35 *
At a glance
- Drugs Camostat mesilate (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms CAMELOT
- Sponsors Sagent Pharmaceuticals
- 01 Apr 2021 Status changed from active, no longer recruiting to completed.
- 05 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2021 Planned End Date changed from 1 Feb 2021 to 30 Mar 2021.